Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. monthly Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E14.75 EPS (ttm)4.54 Insider Own0.30% Shs Outstand1.30B Perf Week-0.80%
Market Cap86.72B Forward P/E9.62 EPS next Y6.96 Insider Trans-1.60% Shs Float1.26B Perf Month-0.27%
Income5.90B PEG6.26 EPS next Q1.70 Inst Own82.30% Short Float1.00% Perf Quarter3.69%
Sales22.32B P/S3.89 EPS this Y-45.60% Inst Trans-0.09% Short Ratio1.90 Perf Half Y-2.34%
Book/sh17.20 P/B3.89 EPS next Y1.68% ROA9.20% Target Price79.62 Perf Year-13.38%
Cash/sh21.53 P/C3.11 EPS next 5Y2.36% ROE26.80% 52W Range60.32 - 79.61 Perf YTD6.99%
Dividend2.52 P/FCF24.16 EPS past 5Y18.10% ROI12.00% 52W High-15.94% Beta1.17
Dividend %3.77% Quick Ratio3.50 Sales past 5Y14.60% Gross Margin78.50% 52W Low10.94% ATR1.35
Employees11000 Current Ratio3.60 Sales Q/Q3.80% Oper. Margin37.10% RSI (14)47.56 Volatility1.92% 1.97%
OptionableYes Debt/Eq1.21 EPS Q/Q32.10% Profit Margin26.40% Rel Volume0.73 Prev Close66.94
ShortableYes LT Debt/Eq1.10 EarningsJul 30 AMC Payout51.20% Avg Volume6.61M Price66.92
Recom2.10 SMA20-1.40% SMA500.70% SMA200-0.86% Volume4,833,715 Change-0.03%
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jul-17-19 05:45PM  Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know Zacks
10:32AM  Top Gilead execs leaving as new CEO continues remake of drug maker American City Business Journals
10:06AM  Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks
08:42AM  Gilead's Chief Scientific Officer to leave next month MarketWatch
08:30AM  Gilead Sciences Chief Scientific Officer John McHutchison to Leave the Company Business Wire
08:30AM  Gilead Sciences Announces Changes to Senior Leadership Team Business Wire
07:15AM  Gilead's Galapagos Deal: What It Means for Investors Motley Fool
Jul-16-19 04:05PM  Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019 Business Wire
11:58AM  Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property Bloomberg
09:50AM  Company News for Jul 16, 2019 Zacks
08:30AM  Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility Business Wire
07:27AM  3 Soaring Biotech Stocks With More Fuel in the Tank Motley Fool
Jul-15-19 07:40PM  Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive Moody's
05:34PM  Wall Street Mixed on Monday
04:50PM  What Happened in the Stock Market Today Motley Fool
04:48PM  Nasdaq Today: Bitcoin & Libra; Whats Broadcom Doing? InvestorPlace
04:26PM  Stocks eke out another round of records as investors brace for 2nd-quarter earnings MarketWatch
04:25PM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
04:20PM  Gilead Pens $5 Billion Research Deal Why Analysts Still Want A Merger Investor's Business Daily
02:32PM  Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake InvestorPlace
11:29AM  Will Gilead Sciences Stock Really Rally 33% From Here?
10:22AM  Gilead Risks Regrets on Pricey Galapagos Partnership Bloomberg
10:01AM  Galapagos Notches $3.95B Upfront Investment From Gilead Benzinga
09:57AM  How Gilead's $5.1 billion deal could steal a page from Genentech-Roche hookup American City Business Journals
09:26AM  Gilead Sciences Says No to Megamerger, Signs a Deal to Collaborate With Galapagos
09:21AM  Why Galapagos NV Stock Is Soaring Today Motley Fool
08:59AM  Gilead-Galapagos Ink $5.1B Deal for Additional Compounds Zacks
08:33AM  Factbox: The Galapagos drugs pipeline that has drawn in Gilead Reuters
07:00AM  Market Morning: Gilead Moves On Galapagos, Hong Kong Keeps Fighting, Trump Tweets Market Exclusive
05:40AM  Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion
04:55AM  Stocks - Citigroup,, Rise Premarket; Boeing, CIRCOR Fall
03:16AM  Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal Bloomberg
02:35AM  Gilead invests $5 billion to deepen ties with biotech Galapagos Reuters
Jul-14-19 09:10PM  PRESS DIGEST- Financial Times - July 15 Reuters
01:00PM  Gilead and Galapagos Enter Into Transformative Research and Development Collaboration Business Wire
12:49PM  Gilead invests $5 bln to deepen ties with biotech Galapagos Reuters
11:10AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
03:51AM  Gilead to raise stake in Belgian biotech in $5.1bn deal Financial Times
Jul-11-19 06:42PM  Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play Zacks
05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
04:30PM  Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite Business Wire
08:30AM  Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Business Wire
Jul-10-19 11:24AM  Court Ruling Topples Trump Order, No Price Display in TV Ads Zacks
08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
Jul-09-19 12:52PM  Here's Why Galapagos NV Stock Rose 13.4% in June Motley Fool
10:06AM  Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status Zacks
09:54AM  Gilead, Lyndra Therapeutics Partner On Ultra-Long-Acting HIV Drugs Benzinga
Jul-07-19 07:45AM  3 Hot Biotechs Trending Now TipRanks
Jul-05-19 08:09PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
Jul-03-19 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
01:49PM  Why These 4 Biotech Leaders Could Rebound On Strong Earnings Investor's Business Daily
06:00AM  Buyout Speculation Picks Up in Biotech
Jul-02-19 04:34PM  Why This Gilead-AbbVie Rivalry Could Come To A Head In 2020 Investor's Business Daily
09:58AM  Health Care Digest: Gilead's big plan for rheumatoid arthritis, Gladstone's new heart chief, Chan Zuckerberg's cell atlas and more American City Business Journals
09:54AM  Gilead to Submit NDA for Inflammation Drug Filgotinib in '19 Zacks
09:31AM  Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer Zacks
07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
05:56AM  What Should You Know About Gilead Sciences, Inc.'s (NASDAQ:GILD) Future? Simply Wall St.
Jul-01-19 08:51PM  After Hours: Sarin Scare at Facebook, Gilead to Make Arthritis Drug Submission Soon Motley Fool
07:10PM  Gilead plans to submit arthritis drug to FDA this year MarketWatch
07:00PM  Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year Business Wire
11:00AM  Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation Zacks
Jun-28-19 09:30AM  Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year? Zacks
08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-27-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
12:32PM  Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft Zacks
07:39AM  Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion Zacks
Jun-26-19 11:30AM  Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease Business Wire
11:27AM  5 Game Changing M&A Deals of the Last Decade Zacks
08:37AM  Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More Zacks
06:24AM  Gilead Inks Deal With Carna Biosciences for Immuno-Oncology Zacks
Jun-25-19 11:02AM  The 10 Biggest Biotech Stocks Motley Fool
07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga
Jun-24-19 07:00PM  Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies Business Wire
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
09:20AM  Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up Zacks
Jun-20-19 06:33AM  Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs Zacks
Jun-19-19 11:49AM  3 Large-Cap Biotech Stocks to Buy for Massive Gains InvestorPlace
10:13AM  Why Gilead could pay more than $2 billion in deal with this small S.F. biotech American City Business Journals
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
09:05AM  Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins MarketWatch
08:30AM  Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases Business Wire
Jun-18-19 08:30AM  3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences InvestorPlace
08:00AM  3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal Motley Fool
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 04:05PM  5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA InvestorPlace
09:51AM  AstraZeneca Gives Detailed Data From Calquence Leukemia Study Zacks
Jun-16-19 09:00AM  Better Buy: Aurora Cannabis vs. Gilead Sciences Motley Fool
Jun-14-19 09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
07:46AM  3 Top Dividend Stocks to Buy in June Motley Fool
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
01:54PM  5 Companies Raising Earnings
Jun-12-19 06:38PM  Galapagos Ends Enrollment in Osteoarthritis Study Before Time Zacks
06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
09:30AM  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? Zacks
Jun-11-19 08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; and Carna Biosciences Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM